公开(公告)号：US20130171653A1

公开(公告)日：2013-07-04

申请号：US13809970

申请日：2011-07-14

申请人： Andreas Doll ,  Marina Rigau Resina ,  Miguel Abal Posada ,  Juan Morote Robles ,  Jaume Reventós Puigjaner

发明人： Andreas Doll ,  Marina Rigau Resina ,  Miguel Abal Posada ,  Juan Morote Robles ,  Jaume Reventós Puigjaner

IPC分类号： C12Q1/68

CPC分类号： C12Q1/6886 ,  C12Q2600/118 ,  C12Q2600/158

摘要： The present invention relates to the use of PSGR, a member of the G-protein-coupled olfactory receptor family which is over-expressed in prostate cancer tissue, as a marker suitable for an urine-based diagnostic test for prostate cancer which require only typical prostate manipulation and sample acquisition scenarios avoiding invasive tissue collection.

摘要翻译： 本发明涉及在前列腺癌组织中过度表达的G蛋白偶联的嗅觉受体家族的成员PSGR作为适用于前列腺癌的基于尿液的诊断试验的标记物，其仅需要典型的 前列腺操作和样本采集方案，避免侵入性组织收集。

公开(公告)号：US20130178393A1

公开(公告)日：2013-07-11

申请号：US13809972

申请日：2011-07-14

申请人： Andreas Doll ,  Marina Rigau Resina ,  Juan Morote Robles ,  Miguel Abal Posada ,  Jaume Reventós Puigjaner

发明人： Andreas Doll ,  Marina Rigau Resina ,  Juan Morote Robles ,  Miguel Abal Posada ,  Jaume Reventós Puigjaner

IPC分类号： C12Q1/68

CPC分类号： C12Q1/6886 ,  C12Q2600/118 ,  C12Q2600/158 ,  C12Q2600/16

摘要： The invention relates to methods and kits for the diagnosis of prostate cancer (PCa) in a subject, for assessing or monitoring the response to a therapy in a subject having PCa or for monitoring the progression of prostate cancer PCa based on the detection of alteration in the expression levels of at least one gene selected from the group of PC A3, PSMA and PSGR. The invention relates as well to methods for assessing whether a subject has to be subjected to a prostate biopsy, said subject having a serum PSA range within 4-10 ng/mL.

摘要翻译： 本发明涉及用于诊断受试者中前列腺癌（PCa）的方法和试剂盒，用于评估或监测对具有PCa的受试者的治疗反应或用于监测前列腺癌PCa的进展， 选自PC A3，PSMA和PSGR组中的至少一种基因的表达水平。 本发明还涉及用于评估受试者是否必须进行前列腺活检的方法，所述受试者的血清PSA范围在4-10ng / mL内。

公开(公告)号：US09046522B2

公开(公告)日：2015-06-02

申请号：US13386536

申请日：2010-07-23

申请人： Miguel Abal Posada ,  Andreas Doll ,  Antonio Gil Moreno ,  Tamara Maes ,  Cristina Perez ,  Jaume Reventós Puigjaner ,  Elisabet Rossell

发明人： Miguel Abal Posada ,  Andreas Doll ,  Antonio Gil Moreno ,  Tamara Maes ,  Cristina Perez ,  Jaume Reventós Puigjaner ,  Elisabet Rossell

IPC分类号： C12Q1/68 ,  G01N33/574 ,  C07K16/30

CPC分类号： G01N33/57442 ,  C07K16/3069 ,  C07K2317/34 ,  C12Q1/6886 ,  C12Q2600/112 ,  C12Q2600/156 ,  C12Q2600/158 ,  C12Q2600/16 ,  G01N2800/60

摘要： The invention relates to the surprising finding that biomarkers corresponding to ACAA1, AP1M2, CGN, DDR1, EPS8L2, FASTKD1, GMIP, IKBKE, P2RX4, P4HB, PHKG2, PPFIBP2, PPP1 R16A, RASSF7, RNF183, SIRT6, TJP3, EFEMP2, S0CS2, and DCN are differentially expressed in control samples as compared to samples from patients having endometrial cancer and are therefore useful for detecting endometrial cancer. In particular these biomarkers having excellent sensitivity, specificity, and/or the ability to separate affected from non affected individuals. Furthermore, the inventors found that the differential expression of these biomarkers in primary endometrial cancer tumor tissue is correlated to their expression level in uterine fluid samples as compared to control values. Thus these biomarkers are robust in that they are found to be differentially expressed in several different types of samples from affected individuals.

摘要翻译： 本发明涉及令​​人惊奇的发现：对应于ACAA1，AP1M2，CGN，DDR1，EPS8L2，FASTKD1，GMIP，IKBKE，P2RX4，P4HB，PHKG2，PPFIBP2，PPP1R16A，RASSF7，RNF183，SIRT6，TJP3，EFEMP2，S0CS2， 与对照样品相比，DCN与子宫内膜癌患者相比差异表达，因此可用于检测子宫内膜癌。 特别地，这些具有优异的敏感性，特异性和/或分离受影响的非受影响个体的能力的生物标志物。 此外，发明人发现与对照值相比，这些生物标志物在原发性子宫内膜癌肿瘤组织中的差异表达与子宫液样品中的表达水平相关。 因此，这些生物标志物是稳健的，因为它们被发现在受影响个体的几种不同类型的样品中差异表达。

公开(公告)号：US20120122726A1

公开(公告)日：2012-05-17

申请号：US13386536

申请日：2010-07-23

申请人： Miguel Abal Posada ,  Andreas Doll ,  Antonio Gil Moreno ,  Tamara Maes ,  Cristina Perez ,  Jaume Reventós Puigjaner ,  Elisabet Rossell

发明人： Miguel Abal Posada ,  Andreas Doll ,  Antonio Gil Moreno ,  Tamara Maes ,  Cristina Perez ,  Jaume Reventós Puigjaner ,  Elisabet Rossell

IPC分类号： C40B30/04 ,  C12Q1/68 ,  C40B40/10 ,  C07H21/02 ,  C07K16/18 ,  C40B40/06 ,  G01N33/566 ,  C07H21/04

CPC分类号： G01N33/57442 ,  C07K16/3069 ,  C07K2317/34 ,  C12Q1/6886 ,  C12Q2600/112 ,  C12Q2600/156 ,  C12Q2600/158 ,  C12Q2600/16 ,  G01N2800/60

摘要： The invention relates to the surprising finding that biomarkers corresponding to ACAA1, AP1M2, CGN, DDR1, EPS8L2, FASTKD1, GMIP, IKBKE, P2RX4, P4HB, PHKG2, PPFIBP2, PPP1 R16A, RASSF7, RNF183, SIRT6, TJP3, EFEMP2, S0CS2, and DCN are differentially expressed in control samples as compared to samples from patients having endometrial cancer and are therefore useful for detecting endometrial cancer. In particular these biomarkers having excellent sensitivity, specificity, and/or the ability to separate affected from non affected individuals. Furthermore, the inventors found that the differential expression of these biomarkers in primary endometrial cancer tumor tissue is correlated to their expression level in uterine fluid samples as compared to control values. Thus these biomarkers are robust in that they are found to be differentially expressed in several different types of samples from affected individuals.

摘要翻译： 本发明涉及令​​人惊奇的发现：对应于ACAA1，AP1M2，CGN，DDR1，EPS8L2，FASTKD1，GMIP，IKBKE，P2RX4，P4HB，PHKG2，PPFIBP2，PPP1R16A，RASSF7，RNF183，SIRT6，TJP3，EFEMP2，S0CS2， 与对照样品相比，DCN与子宫内膜癌患者相比差异表达，因此可用于检测子宫内膜癌。 特别地，这些具有优异的敏感性，特异性和/或分离受影响的非受影响个体的能力的生物标志物。 此外，发明人发现与对照值相比，这些生物标志物在原发性子宫内膜癌肿瘤组织中的差异表达与子宫液样品中的表达水平相关。 因此，这些生物标志物是稳健的，因为它们被发现在受影响个体的几种不同类型的样品中差异表达。